Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”) - After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway - Reltecimod in conjunction with currently available standard of care demonstrated a significant...